Fintel reports that on February 12, 2025, HC Wainwright & Co. downgraded their outlook for Inhibikase Therapeutics ...

H.C. Wainwright downgraded Inhibikase Therapeutics (IKT) to Neutral from Buy without a price target after risvodetinib development was paused ...

Clinical-stage USA-based drug developer Inhibikase Therapeutics saw its shares tumble more than 31% to $1.92, after is revealed that it is pausing development of risvodetinib following disappointing ...

We would like to share some important news with you. After years of bringing you the latest insights, analysis and innovation news from the pharma industries, we have made the difficult decision to ...

Inhibikase Therapeutics, Inc. (IKT) stock price is 2.27 and Inhibikase Therapeutics, Inc. (IKT) 10-day simple moving average is 2.65. Inhibikase Therapeutics, Inc. (IKT) stock price is 2.27 and ...

Ger­man CD­MO Rentschler Bio­phar­ma is clos­ing down its cell and gene ther­a­py op­er­a­tions and shut­ter­ing a fa­cil­i­ty in the UK, which could af­fect up to … ...

In­hibikase Ther­a­peu­tics is slam­ming the brakes on its Parkin­son’s dis­ease pro­gram af­ter the can­di­date failed to im­prove symp­toms in a mid-stage test in treat­ment ...

(Reuters) – Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson’s disease drug after it failed to improve patients’ ability to carry out daily tasks such ...

Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic options” for the med after it came up short in the efficacy stakes.